# Stereotactic Ablative Body Radiotherapy (SABR) for Oligometastases

> **NCT02933242** · NA · ACTIVE_NOT_RECRUITING · sponsor: **British Columbia Cancer Agency** · enrollment: 399 (actual)

## Conditions studied

- Metastatic Tumors

## Interventions

- **RADIATION:** Stereotactic Ablative Body Radiotherapy

## Key facts

- **NCT ID:** NCT02933242
- **Lead sponsor:** British Columbia Cancer Agency
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-11
- **Primary completion:** 2025-12
- **Final completion:** 2026-07
- **Target enrollment:** 399 (ACTUAL)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02933242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02933242, "Stereotactic Ablative Body Radiotherapy (SABR) for Oligometastases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02933242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*